Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Ranbaxy Fraud Settlement Emphasizes Guilty Pleas, Downplays Exclusion

May 20 2013

• By Sue Sutter

Related Content

Ranbaxy’s $500 Million GMP Settlement Would Be Second Most Expensive For Rx Manufacturing Violations

Jan 02 2012

KV Official Is Excluded From Government Programs, The First Under OIG's New Guidance

Nov 17 2010

GSK’s $750 Mil. DoJ Settlement: When GMP Violations Equal Healthcare Fraud

Nov 01 2010

Presumed Guilty: HHS Exclusion Guidance Shifts Burden Of Proof To Corporate Officers

Oct 25 2010

KV Pharmaceutical To Decide Whether To Retain Generics Business After Settling Manufacturing Cover-up Charges With DoJ

Mar 08 2010

Related Companies

Ranbaxy Laboratories Limited

GSK plc

Novartis AG

AMAG Pharmaceuticals Inc.

Additional Topics

United States India Asia Pacific Legal Issues Quality BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window